MY
Myriad Genetics, Inc.
MYGN · NASDAQ
$4.01 +2.04% (+$0.08)
1M +31.48%
Market Cap $378.7M
P/E Ratio -
Div. Yield -
ROE 32.59%
Bulios Fair Price
$4.06
1.2% upside
Current Price
$4.01
Undervalued Fair Value Overvalued
According to Bulios Fair Price, MYGN is currently trading close to its fair value. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
100 /100
Cheap P/B 1.25x
P/S 0.47x
P/FFO N/A
Growth
41 /100
Stable Book val. growth 25.38%
Rev. growth 6.72%
FCF growth N/A
Profitability
20 /100
Weak Op. margin 12.22%
Gross margin 68.83%
FCF margin 1.07%
Quality
15 /100
Poor ROA 17.62%
ROIC 19.26%
Asset turnover 1.26x
Debt
55 /100
Moderate Int. coverage -5.82x
Debt/Equity 0.69x
Current ratio 2.21x
Stability
35 /100
Moderate EPS volatility 124.28%
Beta 1.68x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about MYGN
Online
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Samraat S. Raha
Employees
2,700
Headquarters
Salt Lake City
Upcoming events
02 NOV
Earnings
Upcoming earnings report